Non-alcoholic fatty liver disease as a cause and consequence of cardio-metabolic complications. Role of the ursodeoxicholic acid in the pharmacotherapy.
The article presents an update of the role of non-alcoholic fatty liver disease (NAFLD) in cardiometabolic diseases and events: arterial hypertension and components of the metabolic syndrome. A review of NAFLD modern pharmacotherapy has been conducted. Particular attention is paid to the place of ursodeoxycholic acid in the complex treatment of NAFLD.
['Maevskaya|M V|MV|', 'Ivashkin|V T|VT|', 'Ivashkin|K V|KV|', 'Lunkov|V D|VD|', 'Liusina|E O|EO|', 'Zozula|V N|VN|', 'Leshchenko|V I|VI|']
D002756:Cholagogues and Choleretics D006801:Humans D006973:Hypertension D024821:Metabolic Syndrome D065626:Non-alcoholic Fatty Liver Disease D012307:Risk Factors D014580:Ursodeoxycholic Acid
non-alcoholic fatty liver disease arterial hypertension ursodeoxycholic acid insulin resistance